David L Rimm MD, PhD
Professor of Pathology; Director of Pathology Tissue Services; Director of Translational Pathology
Quantitative Pathology; Cancer Tissue Biomarkers; Melanoma; Breast Cancer; Cell-cell adhesion in cancer; Translation of molecular techniques to diagnostic cytopathology; General Cytopathology; Immunohistochemistry; thyroid pathology
My lab has a strong translational theme and has two main directions: 1) development of new quantitative approaches to pathology and their use to classify tumors by prognosis or predict response to cancer therapy (cancer tissue biomarker research); and 2) the molecular analysis of growth factor receptors and signaling. Studies fall into 3 groups. Group 1: translational studies using tissue microarray technology and AQUA (automated quantitative analysis) applying basic molecular observations and tools to diagnostic problems in pathology. Main topics include predicting response to therapy in breast cancer and predicting metastasis in breast cancer and melanoma. Group 2: the examination of mechanisms of signaling by Met, (the HGF/SF receptor), ErbB family members and other receptor tyrosine kinases (RTK) in epithelial tumors. We are particularly interested in translocation of these receptors to the nucleus. Finally, Group 3: the use of spectral/spatial analysis tools to improve diagnostic accuracy in cytopathology.
Extensive Research Description
Nearly 100% of Dr. Rimm’s lab efforts are related to cancer. He has largely focused on tissue biomarker research. His most innovative research has involved construction of patient cohorts using the tissue microarray format and the development of methods for quantitative analysis of protein expression on tissue microarrays and whole tissue sections. He was the lead author on a recent paper in Journal of Clinical Oncology that sets forth guidelines for construction of tissue microarrays from cooperative group clinical trial samples. This expertise has landed him positions on correlative science committees in the ALTTO and TEACH breast cancer clinical trials. He has also published extensively in the field of biospecimen science including a series of papers published in Laboratory Investigation, the most popular being cited over 500 times. He is a regular invited speaker at the Biospecimen Research Network annual meeting and is supported by a large contract from the Office of Biospecimen and Biorepository Research. However, his most innovative efforts have been related to automated quantitative analysis of formalin fixed, paraffin embedded tissue. He and his lab developed the AQUA method of quantitative immunofluorescence that was published in 2002 in Nature Medicine (over 350 citations). This technology attempted to remove the subjectivity from the analysis of immunohistochemistry specimens by using co-localization to define regions of interest, rather than feature extraction of pathologist defined subregions. There are over 100 publications in the literature from labs in the US and around the world that use this technology, including many in high impact journals (NEJM, Nature, Cancer Cell, JCO, etc). The technology has been patented and was the founding intellectual property of HistoRx in 2004. The company has largely used the technology to assist pharmaceutical companies in development of companion diagnostics. Last year, the technology was licensed to Genoptix, a CLIA lab in California that now delivers AQUA read, standardized measurements of ER, PR and HER2 on patient specimens. This effort represents a pathway from Dr. Rimm’s lab to the clinic.